SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 277.7% in July

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 37,966 shares, a growth of 277.7% from the July 15th total of 10,052 shares. Currently, 6.8% of the company’s shares are short sold. Based on an average daily volume of 747,372 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SPRC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. Wall Street Zen upgraded shares of SciSparc to a “hold” rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

SciSparc Trading Down 3.2%

Shares of SPRC stock opened at $6.60 on Thursday. SciSparc has a 1-year low of $2.98 and a 1-year high of $80.10. The stock’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $5.86.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.